Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence

References

• Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the global burden of disease study 2017. Ann Rheum Dis. 2019;78(11):1463–1471. doi:10.1136/annrheumdis-2019-215920
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18002.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Rheumatoid Arthritis (RA). [cited 2021, January 29]. Available from: https://www.cdc.gov/arthritis/basics/rheumatoid-arthritis.html. Accessed May 4, 2022.
   Google Scholar
• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038. doi:10.1016/S0140-6736(16)30173-8
   PubMed Web of Science ®Google Scholar
• Sparks JA. Rheumatoid arthritis. Ann Intern Med. 2019;170(1):ITC1–ITC16. doi:10.7326/AITC201901010
   PubMed Web of Science ®Google Scholar
• Sokka T, Krishnan E, Häkkinen A, et al. Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum. 2003;48(1):59–63. doi:10.1002/art.10731
   PubMed Web of Science ®Google Scholar
• West E, Jonsson SW. Health-related quality of life in rheumatoid arthritis in Northern Sweden: a comparison between patients with early RA, patients with medium-term disease and controls, using SF-36. Clin Rheumatol. 2005;24(2):117–122. doi:10.1007/s10067-004-0976-6
   PubMed Web of Science ®Google Scholar
• Puolakka K, Kautiainen H, Mottonen T, et al. Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. Ann Rheum Dis. 2005;64:130–133. doi:10.1136/ard.2003.019034
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–699. doi:10.1136/annrheumdis-2019-216655
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15. doi:10.1136/annrheumdis-2015-207524
   PubMed Web of Science ®Google Scholar
• European public assessment report Remsima. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/remsima. Accessed August 27, 2021.
   Google Scholar
• European public assessment report Benepali. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/benepali. Accessed August 27, 2021.
   Google Scholar
• European public assessment report Amgevita. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/amgevita. Accessed August 27, 2021.
   Google Scholar
• Italian Medicines Agency (AIFA). The use of drugs in Italy National Report, Year 2015 (OSMED report). Available from: https://www.aifa.gov.it/uso-dei-farmaci-in-italia. Accessed August 27, 2021.
   Google Scholar
• Italian Medicines Agency (AIFA). The use of drugs in Italy National Report, Year 2020 (OSMED report). Available from: https://www.aifa.gov.it/uso-dei-farmaci-in-italia. Accessed August 27, 2021.
   Google Scholar
• Westhovens R, Houssiau F, Joly J, et al. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis. J Rheumatol. 2006;33:847–853.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Remsima summary of product characteristics. [cited 2021 January 29]. Available from: https://www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf. Accessed May 4, 2022.
   Google Scholar
• US Food and Drug Administration. Highlights of prescribing information, inflectra (infliximab-dyyb). [cited 2021 January 29]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125544s008lbl.pdf. Accessed May 4, 2022.
   Google Scholar
• European Medicines Agency. Assessment report on extension(s) of marketing authorisation: remsima. Available from: https://www.ema.europa.eu/en/documents/variation-report/remsima-h-c-2576-x-0062-epar-assessment-report-variation_en.pdf. Accessed August 30, 2021.
   Google Scholar
• European Medicines Agency. Assessment report on extension(s) of marketing authorisation: remsima. Available from: https://www.ema.europa.eu/en/documents/variation-report/remsima-h-c-2576-ii-0082-epar-assessment-report-variation_en.pdf. Accessed August 30, 2021.
   Google Scholar
• Remsima Product Information. 30/04/2021 Remsima - EMEA/H/C/002576 - II/0095. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/remsima. Accessed August 30, 2021.
   Google Scholar
• Takeuchi T, Miyasaka N, Inoue K, et al. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol. 2009;19(5):478–487. doi:10.3109/s10165-009-0195-8
   PubMed Web of Science ®Google Scholar
• Mulleman D. Lin, DCM, et al. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. Ther Drug Monit. 2010;32(2):232–236. doi:10.1097/FTD.0b013e3181cc6fef
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Voskuyl AE, Lems WF, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64(5):704–707. doi:10.1136/ard.2004.030452
   PubMed Web of Science ®Google Scholar
• Perdriger A. Infliximab in the treatment of rheumatoid arthritis. Biologics. 2009;3:183–191. doi:10.2147/btt.2009.3099
   PubMedGoogle Scholar
• Westhovens R, Wiland P, Zawadzki M, et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. Rheumatology. 2021;60(5):2277–2287. doi:10.1093/rheumatology/keaa580
   PubMed Web of Science ®Google Scholar
• Caporali R, Allanore Y, Alten R, et al. Efficacy and safety of subcutaneous infliximab versus Adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. Expert Rev Clin Immunol. 2021;17(1):85–99. doi:10.1080/1744666X.2020.1858803
   PubMed Web of Science ®Google Scholar
• Combe B, Allanore Y, Alten R, et al. Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. Arthritis Res Ther. 2021;23(1):119. doi:10.1186/s13075-021-02487-x
   PubMed Web of Science ®Google Scholar
• D’Amico F, Solitano V, Aletaha D, et al. Biobetters in patients with immune-mediated inflammatory disorders: an international Delphi consensus. Autoimmun Rev. 2021;20(7):102849. doi:10.1016/j.autrev.2021.102849
   PubMed Web of Science ®Google Scholar
• Mazzuoli S, Tricarico D, Demma F, et al. Accelerated infliximab infusion: safety, factors predicting adverse events, patients’ satisfaction and cost analysis. a cohort study in IBD patients. PLoS One. 2016;11(11):e0166443. doi:10.1371/journal.pone.0166443
   PubMed Web of Science ®Google Scholar
• Sánchez-Piedra C, Sueiro-Delgado D, García-González J, et al. Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years. Sci Rep. 2021;11(1):15051. doi:10.1038/s41598-021-94504-x
   PubMed Web of Science ®Google Scholar
• Graudal N, Kaas-Hansen BS, Guski L, et al. Different original and biosimilar tnf inhibitors similarly reduce joint destruction in rheumatoid arthritis-a network meta-analysis of 36 randomized controlled trials. Int J Mol Sci. 2019;20(18):4350. doi:10.3390/ijms20184350
   PubMed Web of Science ®Google Scholar
• Verma AM, Patel A, Subramanian S, et al. From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative. Lancet Gastroenterol Hepatol. 2021;6(2):88–89. doi:10.1016/S2468-1253(20)30392-7
   PubMed Web of Science ®Google Scholar
• McGoran J, Wilson A, McErlain S, et al. Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic. Frontline Gastroenterol. 2021;13(1):89–90. doi:10.1136/flgastro-2020-101760
   PubMed Web of Science ®Google Scholar